Cero Therapeutics Holdings Inc. 8-K Filing

Ticker: CEROW · Form: 8-K · Filed: Sep 22, 2025 · CIK: 1870404

Sentiment: neutral

Topics: corporate-information, trading-status

Related Tickers: CERO, CEROW

TL;DR

CERO and CEROW are trading on Nasdaq as of 9/22/25.

AI Summary

Cero Therapeutics Holdings, Inc. reported on September 22, 2025, that its common stock and warrants are traded on the Nasdaq Capital Market under the symbols CERO and CEROW, respectively. The company is incorporated in Delaware and its principal executive offices are located in South San Francisco, California.

Why It Matters

This filing confirms the trading status and symbols for Cero Therapeutics Holdings, Inc.'s common stock and warrants on the Nasdaq Capital Market.

Risk Assessment

Risk Level: low — This is a routine 8-K filing confirming basic corporate information and trading details, with no new material events or financial disclosures.

Key Players & Entities

FAQ

What is the primary purpose of this Form 8-K filing?

The primary purpose of this Form 8-K filing is to report the date of the earliest event, which is September 22, 2025, and to provide basic corporate information including the registrant's name, state of incorporation, IRS EIN, principal executive office address, and telephone number.

What are the trading symbols for Cero Therapeutics Holdings, Inc.'s common stock and warrants?

The trading symbol for Cero Therapeutics Holdings, Inc.'s common stock is CERO, and the trading symbol for its warrants is CEROW.

On which exchange are Cero Therapeutics Holdings, Inc.'s securities registered?

Cero Therapeutics Holdings, Inc.'s common stock and warrants are registered on the Nasdaq Capital Market.

In which state was Cero Therapeutics Holdings, Inc. incorporated?

Cero Therapeutics Holdings, Inc. was incorporated in Delaware.

What is the address of Cero Therapeutics Holdings, Inc.'s principal executive offices?

The address of Cero Therapeutics Holdings, Inc.'s principal executive offices is 201 Haskins Way, Suite 230, South San Francisco, CA 94080.

Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-09-22 16:10:46

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 22, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the " Company "), updated its corporate presentation, which it plans to use in meetings with investors, analysts and others. The presentation can be found on the Company's website, w ww.cero.bio. The information set forth on the Company's website is not included or incorporated by reference herein. A copy of this corporate presentation is furnished hereto as Exhibit 99.1. The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Inve stor Presentation, dated September 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CERO THERAPEUTICS HOLDINGS, INC. Dated: September 22, 2025 By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing